drugset / Trial / NCT06067828
A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).
RandomizedCrossoverDouble-blindTreatment
Summary
This study will investigate the effect of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) metered dose inhaler (MDI) compared with Placebo MDI, and Budesonide and Formoterol Fumarate (BFF) MDI on isotime inspiratory capacity (IC) and exercise endurance time.
Timeline
- Start
- 2023-10-24
- Primary completion
- 2026-01-22
- Completion
- 2026-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Budesonide | Small molecule | 160 ug | Inhaled |
| Comparator | Formoterol | Other / unclassified | 4.8 ug | Inhaled |
| Comparator | Glycopyrronium | Unknown | 7.2 ug | Inhaled |